

We Claim:

1. A solid dispersion comprising substantially amorphous 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide, or a pharmaceutically-acceptable salt thereof and one or more carrier materials.
2. The solid dispersion of claim 1, wherein the one or more carrier materials is selected from polymers.
3. The solid dispersion of claim 1, wherein the one or more carrier materials is selected from polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer, and hypromellose acetate succinate.
4. The solid dispersion of claims 1, 2 or 3, wherein the ratio of 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide to the one or more carrier materials is from about 10:90 to 90:10 by weight; or from about 20:80 to 80:20 by weight; or from about 25:75 to 75:25 by weight; or from about 40:60 to 60:40 by weight.
5. The solid dispersion of any one of claims 1 to 4, wherein the carrier material is polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer; or wherein the carrier material is vinylpyrrolidone-vinyl acetate copolymer.
6. The solid dispersion of any one of claims 1 to 3 or claim 5 or 6, wherein the ratio of 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide to carrier material is about 20:80 by weight.
7. The solid dispersion of any one of claims 1 to 6, wherein at least about 95% of the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide in the dispersion is in an amorphous form; or wherein at least about 99% of the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide in the dispersion is in an amorphous form.
8. The solid dispersion according to claim 7, characterized by the solid dispersion containing solid particles with a particle size diameter of less than 10 μm .

9. A pharmaceutical formulation comprising a therapeutically effective amount of a solid dispersion according to any one of claims 1 to 8.
10. The pharmaceutical formulation of claim 9, wherein the pharmaceutical formulation is a tablet or a capsule.
11. Use of the solid dispersion of any one of claims 1 to 8, or the pharmaceutical formulation of claim 9 or 10, in the manufacture of a medicament for treating a disease or disorder regulated by ROCK.
12. The use of claim 11, wherein the disease or disorder is graft-versus-host disease (GVHD).
13. The use of claim 12, wherein the GVHD is chronic or acute.
14. The use of claim 11, wherein the disease or disorder is an autoimmune or fibrotic disorder.
15. The use of claim 14, wherein the autoimmune or fibrotic disorder is pulmonary fibrosis; idiopathic pulmonary fibrosis; cystic fibrosis; radiation induced fibrosis; arterial, cardiac endomyocardial, renal, or liver fibrosis; moderate to severe psoriasis; rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus (SLE); Crohn's disease; dermatitis; or eczema.
16. The use of claim 11, wherein the disease or disorder is bronchiolitis obliterans syndrome (BOS).
17. The use of claim 16, wherein the BOS is post lung transplantation or post allogeneic hematopoietic stem cell transplantation (allo-HSCT).
18. A process of preparing an amorphous form of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazoliny]phenoxy}-N-(propan-2-yl) acetamide comprising dissolving the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazoliny]phenoxy}-N-(propan-2-yl) acetamide and one or more carrier materials in a suitable solvent to form a solution.
19. The process of claim 18, wherein the suitable solvent comprises a mixture of triethylamine and acetone.

20. The process of claim 18 or 19, further comprising spray-drying the solution of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide and one or more carrier materials to remove the suitable solvent; and/or wherein the carrier material is selected from vinylpyrrolidone-vinyl acetate copolymer and polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer.